skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon
Pharma Intelligence brings you critical pharmaceutical research studies, featuring new pharmaceutical research developments, and delivers them to you in a timely fashion. Rely on the experienced experts from Pharma Intelligence for essential information and unparalleled insights you can use to inform your own business decisions and strategies.

Don't miss any of the impactful developments to come out of ESMO 2019

Follow all the highlights from this annual meeting of oncology clinicians, researchers, patient advocates, journalists, and members of the pharmaceutical industry with this report extract. Datamonitor Healthcare’s coverage includes:

• Translational cancer science unveiled at ESMO 2019
• Announcements of potentially practice-changing data
• Important developments from the 5-day event


PharmAI – Industry Is Smartening Up To Potential Of Artificial Intelligence

Artificial Intelligence (AI) has enormous potential in changing the delivery of health care and improving patient outcomes, with applications in pattern detection, patient monitoring, disease diagnosis and treatment selection. The rationale is that AI can be used to enhance the decisionmaking process, taking into account far more data than are available to physicians via conventional means. The addition of machine learning (ML)algrithms enables the AI to become better over time, increasing the accuracy or timeliness of its recommendations. Recognizing this broad potential, the FDA has recently sought to spur the industry with its discussion paper on regulating Software as a Medical Device (SaMD) products.

Disease overview

Payers have become increasingly aware of the potential cost burden of multiple myeloma treatment over the past five years, due to several factors:

  • The approvals of several high-cost biologics in increasingly early treatment lines
  • Increased patient life expectancies resulting in extended treatment durations
  • The surge in demand for high-cost combination regimens


Data and analysis products


Sitetrove: 治験責任医師と治験施設情報のデータベース

Sitetrove(サイトトローブ)は、170か国・40万人以上の治験責任医師(PI: Principal Investigator)と235以上の疾患に対応する11万7千か所以上の治験施設に関する情報を収録するデータベースです。治験責任医師と治験施設に関して業界で最も正確で包括的な情報を提供することで、コスト増につながる治験の遅延を最小化し、お客様の臨床試験を成功に導くようサポートします。Sitetroveに登録される治験責任医師は、豊富な臨床経験や治験に関する十分な知識をもっていることをアナリストにより精査されています。

Key benefits:

  • 治験責任医師と治験施設情報のデータベース
  • 疫学ダッシュボードは見やすいマップビュー
  • Ask-the-Analyst機能で情報に基づく意思決定
data-monitor-health-care-pharma intelligence

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare(データモニターヘルスケア)では主要な疾患と医薬品をカバーする市場調査レポートを収載し、定期的に更新しています。市場調査レポート1本単位の購入または疾患単位の購読契約による対象の市場調査レポートすべての閲覧が可能です。新医薬品の市場性の評価や研究開発戦略の立案にご利用ください。

Key benefits:

  • 客観的市場調査の力で成長戦略を確かにする
  • 最新市場予測ツールでアンメットニーズ特定
  • Ask-the-Analyst機能で情報に基づく意思決定
pharma intelligence pharma banner

Pharmaprojects: 医薬品開発パイプラインのデータベース


Key benefits:

  • 医療用医薬品の研究・開発パイプライン情報
  • 35年間にわたる過去のヒストリカルデータも
  • Ask-the-Analyst機能で情報に基づく意思決定





電話:+81 (0)3 6273 4260